Chapter 11. Future Antithrombotic Therapy

Joseph A. Jakubowski(Indiana Biosciences Research Institute), Daniel J. Sall(Eli Lilly (United States)), Gerald F. Smith(Eli Lilly (United States))

Annual reports in medicinal chemistry

January 1, 1992

10.1016/s0065-7743(08)60409-1

Cited by 31

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention

|Circulation|2007|882

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

|New England Journal of Medicine|2013|651

A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents

|Journal of the American College of Cardiology|2012|617

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

|American Heart Journal|2006|571

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

|European Heart Journal|2006|537